Augmedix, Inc. (NASDAQ:AUGX - Get Free Report) insider Ian Shakil sold 24,778 shares of the firm's stock in a transaction on Thursday, April 11th. The stock was sold at an average price of $3.93, for a total value of $97,377.54. Following the transaction, the insider now owns 3,000 shares in the company, valued at approximately $11,790. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Ian Shakil also recently made the following trade(s):
- On Friday, April 5th, Ian Shakil sold 51,387 shares of Augmedix stock. The shares were sold at an average price of $4.03, for a total value of $207,089.61.
- On Monday, April 8th, Ian Shakil sold 37,780 shares of Augmedix stock. The shares were sold at an average price of $3.97, for a total value of $149,986.60.
- On Wednesday, April 3rd, Ian Shakil sold 45,906 shares of Augmedix stock. The shares were sold at an average price of $4.11, for a total value of $188,673.66.
- On Monday, April 1st, Ian Shakil sold 58,978 shares of Augmedix stock. The shares were sold at an average price of $3.91, for a total value of $230,603.98.
- On Thursday, March 28th, Ian Shakil sold 31,994 shares of Augmedix stock. The shares were sold at an average price of $4.06, for a total value of $129,895.64.
Augmedix Stock Performance
How Biden has already won 2024
From Porter & Company | Ad
Obama’s Forever Term [Exposed] or Obama Biden has already won 2024
Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.
Click here to watch this now before it’s too late.
AUGX stock opened at $3.96 on Friday. The stock has a 50-day moving average price of $4.15 and a 200-day moving average price of $4.84. Augmedix, Inc. has a 1-year low of $1.50 and a 1-year high of $6.25. The company has a current ratio of 2.41, a quick ratio of 2.41 and a debt-to-equity ratio of 0.66. The firm has a market cap of $193.01 million, a PE ratio of -8.80 and a beta of -0.16.
Augmedix (NASDAQ:AUGX - Get Free Report) last posted its quarterly earnings data on Monday, March 18th. The company reported ($0.09) earnings per share for the quarter. Augmedix had a negative return on equity of 308.50% and a negative net margin of 42.74%. The business had revenue of $12.68 million during the quarter, compared to the consensus estimate of $12.30 million. As a group, equities research analysts expect that Augmedix, Inc. will post -0.51 earnings per share for the current year.
Wall Street Analyst Weigh In
AUGX has been the topic of several recent research reports. Evercore ISI raised Augmedix from an "in-line" rating to an "outperform" rating and raised their price objective for the company from $4.50 to $5.00 in a report on Tuesday. B. Riley assumed coverage on Augmedix in a research report on Wednesday, April 3rd. They set a "buy" rating and a $5.50 target price for the company. Finally, Maxim Group lowered their target price on Augmedix from $6.50 to $5.00 and set a "buy" rating for the company in a research report on Tuesday, March 19th.
Get Our Latest Stock Analysis on AUGX
Institutional Trading of Augmedix
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC bought a new stake in Augmedix in the 3rd quarter valued at about $48,000. Symmetry Peak Management LLC bought a new stake in Augmedix in the 4th quarter valued at about $88,000. Worth Venture Partners LLC bought a new stake in Augmedix in the 3rd quarter valued at about $83,000. Thompson Davis & CO. Inc. bought a new stake in Augmedix in the 4th quarter valued at about $120,000. Finally, Verition Fund Management LLC bought a new stake in Augmedix in the 4th quarter valued at about $122,000. 87.11% of the stock is owned by institutional investors.
Augmedix Company Profile
(
Get Free Report)
Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
